Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells

Cancer Research

Volumn 63, Issue 12, 2003, Pages 3154-3161

  Mamot, Christoph ^a   Drummond, Daryl C ^c   Greiser, Udo ^c   Hong, Keelung ^c   Kirpotin, Dmitri B ^c   Marks, James D ^b   Park, John W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; LIPOSOME; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE;

ARTICLE; CARCINOMA CELL; COVALENT BOND; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR UPREGULATION;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; LIPOSOMES; METHOTREXATE; NEOPLASM PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION; TUMOR CELLS, CULTURED; VINBLASTINE; VULVAR NEOPLASMS;

EID: 0037731636     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Park, J. W., Hong, K., Kirpotin, D. B., Papahadjopoulos, D., and Benz, C. C. Immunoliposomes for cancer treatment. Adv. Pharmacol., 40: 399-435, 1997.
2. Drummond, D. C., Meyer, O., Hong, K., Kipoitin, D. B., and Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev., 51: 691-743, 1999.
3. Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., Wood, W. I., and et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA, 92: 1327-1331, 1995.
4. Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W. L., Carter, P., Benz, C. C., and Papahadjopoulos, D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry, 36: 66-75, 1997.
5. Cohen, S., Carpenter, G., and King, L., Jr. Epidermal growth factor-receptor-protein kinase interactions. Prog. Clin. Biol. Res., 66: 557-567, 1981.
6. LeMaistre, C. F., Meneghetti, C., Howes, L., and Osborne, C. K. Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res. Treat., 32: 97-103, 1994.
7. Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer, 8: 3-9, 2001.
8. Nicholson, R. I., Gee, J. M., and Harper, M. E. EGFR and cancer prognosis. Eur. J. Cancer, 37: S9-15, 2001.
9. Ekstrand, A. J., Sugawa, N., James, C. D., and Collins, V. P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc. Natl. Acad. Sci. USA, 89: 4309-4313, 1992.
10. Yamazaki, H., Fukui, Y., Ueyama, Y., Tamaoki, N., Kawamoto, T., Taniguchi, S., and Shibuya, M. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumor. Mol. Cell. Biol., 8, 1816-1820, 1988.
11. Wikstrand, C. J., McLendon, R. E., Friedman, A. H., and Bigner, D. D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res., 57: 4130-4140, 1997.
12. Humphrey, P. A., Wong, A. J., Vogelstein, B., Friedman, H. S., Werner, M. H., Bigner, D. D., and Bigner, S. H. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res., 48: 2231-2238, 1988.
13. Wikstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D., Pegram, C. N., Reist, C. J., and et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res., 55: 3140-3148, 1995.
14. Yamazaki, H., Ohba, Y., Tamaoki, N., and Shibuya, M. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn. J. Cancer Res., 81: 773-779, 1990.
15. Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J., Polikoff, J., and Sato, G. H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med., 1: 511-529, 1983.
16. Goldstein, N. I., Prewett, M., Zuklys, K., Rokwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
17. Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D'Andrea, G., Seidman, A., Norton, L., Gunnett, K., Falcey, J., Anderson, V., Waksal, H., and Mendelsohn, J. Phase 1 studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol., 18: 904-914, 2000.
18. Bonner, J. A., Raisch, K. P., Trummell, H. Q., Robert, F., Meredith, R. F. Spencer, S. A., Buchsbaum, D. I., Saleh, M. N., Stackhouse, M. A., LoBuglio, A. F., Peters, G. E., Caroll, W. R., and Waksal, H. W. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol., 18: 47S-53S, 2000.
19. Batra, S. K., Castelino-Prabhu, S., Wikstrand, C. J., Zhu, X., Humphrey, P. A., Friedman, H. S., and Bigner, D. D. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ., 6: 1251-1259, 1995
20. Szoka, F., Jr., and Papahadjopoulos, D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu. Rev. Biophys. Bioeng. 9: 467-508, 1980.
21. Barlett, G. R. Phosphorus assay in column chromatography. J. Biol. Chem., 234: 466-468, 1959
22. Litzinger, D. C., Buiting, A. M., van Rooijen, N., and Huang, L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta, 1190: 99-107, 1994.
23. Claassen, E. Post-information fluorescent labelling of liposomal membranes. In vivo detection, localisation and kinetics. J. Immunol. Methods, 147: 231-240, 1992.
24. Lasic, D. D., Frederik, P. M., Sturt, M. C., Barenholz, Y., and McIntosh, T. J. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett., 312: 255-258, 1992.
25. Haran, G., Cohen, R., Bar, L. K., and Barenholz, Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta, 1151: 201-215, 1993.
26. Hong, R. L., Huang, C. J., Tseng, Y. L., Pang, V. F., Chen, S. T., Liu, J. J., and Chang, F. H. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin. Cancer Res., 5: 3645-3652, 1999.
27. Park, J. W. Hong, K., Kirpotin, D. B., Colbern, G. Shalaby, R., Baselga, J., Shao, Y., Nielsen, U. B., Marks, J. D., Moore, D., Papahadjopoulos, D., and Benz, C. C. Anti-HER2 Immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8: 1172-1181, 2002.
28. Straubinger, R. M., Papahadjopoulos, D., and Hong, K. L. Endocytosis and intracellular fate of liposomes using pyranine as a probe. Biochemistry, 29: 4929-4939, 1990.
29. Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D., and Boyd, M. R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 48: 4827-4833, 1988.
30. Kirpotin, D. B., Hong, K., Park, J. W., Shalaby, R., Shao, Y., Zhen, W., Nielsen, U., Marks, J. D., Benz, C. C., and Papahadjopoulos, D. Anti-HER2 immunoliposomes produced by spontaneous capture of an amphipathic poly(ethylene glycol)-anti-HER2 antibody conjugate into the liposome membrane. Proc. Am. Assoc. Cancer Res., 41: 325, 2000.
31. Iden, D. L., and Allen, T. M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta, 1513: 207-216, 2001.
32. Fan, Z., Masui, H., Atlas, I., and Mendelsohn, J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 of anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res., 4322-4338, 1993.
33. Marks, C., and Marks, J. D. Phage libraries - a new route to clinically useful antibodies. N. Engl. J. Med., 335: 730-733, 1996.
34. Sheets, M. D., Amersdorfer, P., Finnern, R., Sargent, P., Lindquist, E., Schier, R., Hemingsen, G., Wong, C. Gerhart, J. C., Marks, J. D., and Lindqvist, E. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. USA, 95: 6157-6162, 1998.
35. Huie, M. A., Cheung, M. C., Muench, M. O., Becerril, B., Kan, Y. W., and Marks, J. D. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc. Natl. Acad. Sci. USA, 98: 2682-2687, 2001.
36. Nielsen, U. B., Kirpotin, D. B., Pickering, E. M., Hong, K., Park, J. W., Refaat Shalaby, M., Shao, Y., Benz, C. C., and Marks, J. D. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endcytosis. Biochim. Biophys. Acta, 1591: 109-118, 2002.
37. Steinberg, T. H., Newman, A. S., Swanson, J. A., and Silverstein, S. C. Macrophages possess probenecid-inhibitable organic anion transporters that remove fluorescent dyes from the cytoplasmic matrix. J. Cell Biol., 105; 2695-2702, 1987.
38. Antony, A. C. The biological chemistry of folate receptors. Blood, 79: 2807-2820, 1992.
39. Wikstrand, C. J. Cole, V. R., Crotty, L. E., Sampson, J. H., and Bigner, D. D. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol. Immunother., 50: 639-652, 2002.
40. Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D. and Benz, C. C. Tumor targeting using anti-her2 immu noliposomes. J. Control Release, 74: 95-113, 2001.